Jump to main content
eTG Complete
Index
Search
Home
Antibiotic
Pneumonia
Community-acquired pneumonia (CAP) in adults
High-severity CAP in adults
Antibiotic
Bartonella infections
Osteomyelitis
Septic arthritis of a native joint
Bone and joint infections other than osteomyelitis and native joint septic arthritis
Sepsis or septic shock associated with a bone or joint source
Directed therapy for native bone or joint infection
Brucellosis
Infective endocarditis
Cardiovascular system infections other than endocarditis
Central nervous system infections
Coronavirus disease 2019 (COVID-19)
Cryptococcosis
Cytomegalovirus (CMV) infection
Infectious diarrhoea
Ear, nose and throat infections
Eye infections
Febrile neutropenia
Genital and sexually transmissible infections
Human immunodeficiency virus
Intra-abdominal infections
Leptospirosis
Lyme disease
Mediastinitis
Melioidosis
Mpox (monkeypox)
Nocardiosis
Nontuberculous mycobacterial infections
Oesophageal infections
Parasitic infections
Perinatal infections
Prevention of infection
Q fever
Pneumonia
Finding the right pneumonia topic in these guidelines
Community-acquired pneumonia (CAP) in adults
What is community-acquired pneumonia (CAP)?
Principles of managing CAP in adults
Clinical features of CAP in adults
Severity assessment of CAP in adults
Aetiology of CAP in adults
Investigations for CAP in adults
Rationale for empirical regimens for CAP in adults
Low-severity CAP in adults
Moderate-severity CAP in adults
High-severity CAP in adults
Management of high-severity CAP in adults
Empirical therapy for high-severity CAP in adults
Empirical therapy for high-severity CAP in adults in tropical regions of Australia
Additional considerations for high-severity CAP in adults
Review of adults with high-severity CAP
Intravenous to oral switch for high-severity CAP in adults
Duration of therapy for high-severity CAP in adults
Considerations in managing CAP in adults with chronic obstructive pulmonary disease (COPD) or bronchiectasis
Considerations in managing CAP in adults with immune compromise
Considerations for adults with CAP during pregnancy
Ambulatory antimicrobial therapy for CAP in adults
Approach to managing adults with CAP who are not improving
Prevention of CAP in adults
References
Community-acquired pneumonia (CAP) in children 2 months or older
Community-acquired pneumonia (CAP) in term neonates and children younger than 2 months
Community-acquired pneumonia (CAP) in residents of an aged-care facility
Hospital-acquired pneumonia
Ventilator-associated pneumonia
Aspiration pneumonia
Directed therapy for pneumonia
Respiratory tract infections other than pneumonia
Acute rheumatic fever
Rickettsial infections
Salivary gland infections
Sepsis and septic shock: Identification and initial management
Sepsis and septic shock: Empirical regimens
Directed therapy for bloodstream infections, including sepsis and septic shock
Skin and soft tissue infections
Traumatic wound infections
Urinary tract infections in adults
Urinary tract infections in children
Identifying resistant pathogens or Candida species
Principles of obtaining blood for culture
Principles of antimicrobial use
Antimicrobial stewardship (AMS)
Practical information on using antimicrobial drugs
Aminoglycoside use
Vancomycin use in adults
Vancomycin use in young infants and children
Monitoring antimicrobial blood concentrations
Ambulatory antimicrobial therapy
Antimicrobial hypersensitivity
Kidney impairment and antimicrobial dosing
Contact details for health departments and public health units
Amikacin initial dose calculator
Gentamicin initial dose calculator
Tobramycin initial dose calculator
High-severity CAP in adults
Management of high-severity CAP in adults
Empirical therapy for high-severity CAP in adults
Empirical therapy for high-severity CAP in adults in tropical regions of Australia
Additional considerations for high-severity CAP in adults
Review of adults with high-severity CAP
Intravenous to oral switch for high-severity CAP in adults
Duration of therapy for high-severity CAP in adults
